Preventing a Second Cancer After Your First Cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests dostarlimab, an immune-based medicine, to help lower the chance of getting a second (new) cancer after treatment for a first solid tumor. It’s for people with higher risk features, and it aims to see whether the drug can prevent or delay second cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older (or have a qualifying childhood first cancer).
- You had a solid tumor cancer before that was proven by pathology and was treated with curative intent, and randomization must be within 6 months after finishing that treatment.
- You have at least one higher-risk feature for a second cancer, such as long-term smoking or a known genetic risk, or HPV-related first cancer.
- You can provide stored tumor tissue from your first cancer (FFPE sample) from the time of your first diagnosis, for side-by-side comparison.
- Your blood counts and organs (kidneys, liver, blood clotting) are in acceptable ranges on screening blood/urine tests.
- You must not have certain conditions that increase risk with immune medicines (for example, prior immunotherapy for the first cured cancer, active infections like hepatitis B/C or HIV, or autoimmune disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to plan a second course of radiation for cancer that has returned or spread to a few places. It uses special imaging software to make the treatment more precise and aims to improve outcomes.
This study tests giving a second round of radiation therapy to women whose breast cancer has come back in the same breast, at least 3 years after their first radiation. It may be an option for women 55 and older who have a small, local recurrence that can be removed with surgery.
This trial tests a second, shorter course of radiation to just the area where your cancer was removed, instead of treating the whole breast again. It is for women who have had a new breast cancer in the same breast after previous radiation, to see if this approach is safe and effective.
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
This trial tests whether giving a second course of radiation therapy (called reirradiation) can safely treat lung cancer that has returned after earlier radiation. The goal is to control the cancer in the chest and see how well patients do with this repeat treatment.
This trial tests whether a local treatment (like radiation or other targeted methods) can destroy the few remaining cancer spots that are still visible after your first treatment has worked. The goal is to delay or prevent the cancer from growing again.
Hear when a new Recurrent Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.